Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Nanfang Medical CoSHSE:603880 +2.68%50 PS Ratio is 3.21 as of Jul. 28, 2026, which is 1% above its 10-year median of 3.18. GuruFocus rates SHSE:603880 with a GF Score™ of 50/100 and a GF Value™ of ¥4.71 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Jiangsu Nanfang Medical Co ranks worse than 53.42% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Jiangsu Nanfang Medical Co's share price is ¥6.51.
Jiangsu Nanfang Medical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥2.03. Hence, Jiangsu Nanfang Medical Co's PS Ratio for today is 3.21.
Good Sign:
Jiangsu Nanfang Medical Co Ltd stock PS Ratio (=2.89) is close to 1-year low of 2.89.
The historical rank and industry rank for Jiangsu Nanfang Medical Co's PS Ratio or its related term are showing as below:
SHSE:603880'
s PS Ratio Range Over the Past 10 Years
Min: 1.6 Med: 3.18 Max: 6.52
Current: 3.23
During the past 13 years, Jiangsu Nanfang Medical Co's highest PS Ratio was 6.52. The lowest was 1.60. And the median was 3.18.
SHSE:603880's PS Ratio is ranked worse than 53.42% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 2.89
vs SHSE:603880: 3.23
Jiangsu Nanfang Medical Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Jiangsu Nanfang Medical Co was -10.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -6.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 0.20% per year.
During the past 13 years, Jiangsu Nanfang Medical Co's highest 3-Year average Revenue per Share Growth Rate was 22.10% per year. The lowest was -17.90% per year. And the median was 0.30% per year.
Back to Basics: PS Ratio
Jiangsu Nanfang Medical Co (SHSE:603880) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Jiangsu Nanfang Medical Co PS Ratio Related Terms
Jiangsu Nanfang Medical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603880 vs ISRG, BDX, MDLN: PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Jiangsu Nanfang Medical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Nanfang Medical Co PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Jiangsu Nanfang Medical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Jiangsu Nanfang Medical Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Jiangsu Nanfang Medical Co's Share Price of today is ¥6.51. Jiangsu Nanfang Medical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Jiangsu Nanfang Medical Co (SHSE:603880) has a PS Ratio of 3.21 as of Jul. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Jiangsu Nanfang Medical Co and its competitors. This is near median its historical median of 3.18. Over the past decade, Jiangsu Nanfang Medical Co's PS Ratio has ranged from 1.60 to 6.52. According to the industry distribution chart, Jiangsu Nanfang Medical Co ranks #429 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 53.4%.
Is Jiangsu Nanfang Medical Co's PS Ratio too high?
Jiangsu Nanfang Medical Co's current PS Ratio of 3.21 is near median its 10-year median of 3.18. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 6.52. The Medical Devices & Instruments industry median PS Ratio is 2.89. Jiangsu Nanfang Medical Co's value of 3.21 is 11.1% above this industry median. Based on the distribution chart, Jiangsu Nanfang Medical Co ranks #429 out of 803 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Jiangsu Nanfang Medical Co has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Nanfang Medical Co's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Jiangsu Nanfang Medical Co ranks #429 out of 803 companies for PS Ratio. This places Jiangsu Nanfang Medical Co in the lower half of its industry. The industry median PS Ratio is 2.89. Jiangsu Nanfang Medical Co's value of 3.21 is 11.1% above this benchmark. Historically, Jiangsu Nanfang Medical Co's own PS Ratio has ranged from 1.60 to 6.52 over the past decade. While the company's 10-year median is 3.18 vs. the industry median of 2.89, Jiangsu Nanfang Medical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.89, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Nanfang Medical Co's current PS Ratio of 3.21 is 11.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Jiangsu Nanfang Medical Co and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Nanfang Medical Co's current PS Ratio is 3.21, which is near median its own 10-year median of 3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Nanfang Medical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Nanfang Medical Co (SHSE:603880) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.71, compared to a current price of ¥6.51 — trading 38.2% above its estimated fair value. The current PS Ratio is 3.21, which is near median its 10-year median of 3.18 and 11.1% above the Medical Devices & Instruments industry median of 2.89. Jiangsu Nanfang Medical Co's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Jiangsu Nanfang Medical Co (SHSE:603880), the current PS Ratio is 3.21 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Nanfang Medical Co (SHSE:603880) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Nanfang Medical Co stock appears to be overvalued.
The current stock price of ¥6.51 is trading 38.2% above its estimated GF Value™ of ¥4.71.
GuruFocus considers Jiangsu Nanfang Medical Co to be Significantly Overvalued.
Key valuation signals for SHSE:603880:
PS Ratio: 3.21 (near median its 10-year median of 3.18)
GF Value™: ¥4.71 vs. price of ¥6.51 (38.2% above fair value)
Industry Position: 11.1% above the Medical Devices & Instruments median (#429 of 803)
No single metric tells the full story. See the SHSE:603880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Nanfang Medical Co Ltd is a domestic adhesive dressing production enterprise that integrates research and development, production, and sales. It produces a band-aid in China. The company is focused on the development of self-owned brand products such as first-aid kits, sports protection products, and care products on the basis of the original series of Miaoshou medical dressings.
50GF Score
Get the complete analysis for SHSE:603880
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603880 has been successfully added to your 
